Potential neuroprotective effects of an LSD1 inhibitor in retinal ganglion cells via p38 MAPK activity

Tsutsumi T., Iwao K., Hayashi H., Kirihara T., Kawaji T., Inoue T., Hino S., Nakao M., Tanihara H.

2016
Investigative Ophthalmology and Visual Science

Therapeutic Area

Glaucoma

Affiliations

Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan; Department of Applied Biochemistry, School of Pharmacy Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; Translational Science R&D Division, Santen Pharmaceutical Co. Ltd, Osaka, Japan; Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications